Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1531787 | 0.94 | MEN1 (0.76) | KMT2AMEN1MAPTRAB9ANPC1 | |
| SCHEMBL12768508 | 0.94 | MEN1 (0.76) | KMT2AMEN1MAPTRAB9ANPC1 | |
| SCHEMBL19504615 | 0.94 | MEN1 (0.72) | KMT2AMEN1MAPTRAB9ANPC1 | |
| SCHEMBL7335775 | 0.91 | MEN1 (0.71) | KMT2AMEN1MAPTRAB9ANPC1 | |
| SCHEMBL14281435 | 0.88 | KMT2A (0.54) | KMT2AMEN1MAPTRAB9ANPC1 | |
| SCHEMBL1930907 | 0.88 | MEN1 (0.70) | KMT2AMEN1MAPTRAB9ANPC1 | |
| SCHEMBL1813642 | 0.87 | MEN1 (0.73) | KMT2AMEN1RAB9ANPC1KDM4E | |
| SCHEMBL2499084 | 0.86 | KMT2A (0.53) | KMT2AMEN1MAPTRAB9ANPC1 | |
| SCHEMBL2981986 | 0.86 | MEN1 (0.88) | KMT2AMEN1RAB9ANPC1L3MBTL1 | |
| SCHEMBL28477489 | 0.86 | MEN1 (0.64) | KMT2AMEN1MAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7777041-B2 | 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2010-08-17 | — | — | US | disclosed |
| US-20090156574-A1 | 2-ACYLAMINO-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-06-18 | — | — | US | disclosed |
| US-7504511-B2 | 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2009-03-17 | — | — | US | disclosed |
| US-20060135575-A1 | 2-Acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135575-A1 | 2-Acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | PAH, ABAT, AADAT | KMT2A 901/4885MEN1 3039/4885MAPT 409/4885 |
| US-20090156574-A1 | 2-ACYLAMINO-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | PAH, ABAT, AADAT | KMT2A 901/4885MEN1 3039/4885MAPT 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.